Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Subcutaneous ATRS-2002 in Healthy Males
NCT04879589Phase 1Withdrawn
- Sponsor
- Syneos Health
- Start
- Sep 2022
- Primary completion
- Apr 2023
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of abiraterone in metastatic castration-resistant prostate cancer (mCRPC) (4 arms), sponsored by Syneos Health. Primary endpoints: Pharmacokinetic assessment at 672 hours and Pharmacodynamic assessment at 672 hours. Planned start Sep 2022; status: withdrawn.
02
Drugs
abiraterone
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT04879589.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04879589.